A randomized, double-blind study of the effect of Avastin [bevacizumab] plus gemcitabine and erlotinib compared with placebo plus gemcitabine and erlotinib on overall survival in patients with metastatic pancreatic cancer.

Trial Profile

A randomized, double-blind study of the effect of Avastin [bevacizumab] plus gemcitabine and erlotinib compared with placebo plus gemcitabine and erlotinib on overall survival in patients with metastatic pancreatic cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2014

At a glance

  • Drugs Bevacizumab; Erlotinib; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms AVITA
  • Sponsors Roche
  • Most Recent Events

    • 13 Apr 2012 Trial status is recruiting in United kingdom as reported by European Clinical Trials Database record.
    • 04 Oct 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 04 Jun 2009 Results have been presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top